首页> 外文期刊>BMC Nephrology >Sickle cell disease: a case report of renal amyloidosis
【24h】

Sickle cell disease: a case report of renal amyloidosis

机译:镰状细胞疾病:肾淀粉样症的病例报告

获取原文
           

摘要

The development of proteinuria and reduced glomerular filtration rate is associated with higher mortality among patients with sickle cell disease (SCD). AA amyloidosis, also associated with increased mortality, in SCD is rare. We present a case of a woman with homozygous sickle cell disease with nephrotic syndrome and antibodies to double stranded DNA without clinical features of systemic lupus erythematosus. Kidney biopsy reveals AA amyloidosis and is the first report of concomitant AA amyloidosis with antibodies to double stranded DNA in SCD. A 40-year-old Central African woman with homozygous sickle cell disease and history of vaso-occlusive pain crises undergoes kidney biopsy for nephrotic-range proteinuria. Kidney biopsy reveals AA type amyloidosis, which is a rare manifestation of SCD in the kidney. Her anemia worsens with an ACE inhibitor, initiated to reduce proteinuria and limit GFR decline, so it was discontinued. Hydroxyurea, shown to decrease the frequency of vaso-occlusive crises and lower proteinuria, was subsequently initiated but then discontinued due to worsening anemia. Unfortunately, her glomerular filtration rate worsens. AA amyloidosis and antibodies to double stranded DNA can occur in sickle cell disease. ACE inhibition and hydroxyurea decrease proteinuria so they may limit progression of chronic kidney disease. Hydroxyurea also decreases frequency of vaso-occlusive pain crises so it might be helpful in limiting progression of renal AA amyloidosis. However, further studies are needed to determine optimal treatment strategies for AA amyloidosis in sickle cell disease.
机译:蛋白尿的发展和肾小球过滤率降低与镰状细胞疾病(SCD)患者的死亡率较高。 SCD中的AA淀粉样蛋白病也与增加的死亡率增加有关。我们提出了一种伴有肾病综合征和抗临床特征的肾病综合征和抗体的患有肾病综合征和抗体的患者,而没有全身性狼疮红斑狼疮。肾脏活检揭示了AA淀粉样症,是SCD中双链DNA双链DNA抗体的第一个伴随AA淀粉样变性的报告。一个40岁的中非女性,具有纯合镰刀细胞病和血管闭锁疼痛危机的历史进行了肾功能膜的肾脏活检。肾脏活检显示AA型淀粉样蛋白病,这是肾脏中SCD的罕见表现。她的贫血用ACE抑制剂恶化,开始减少蛋白尿和限制GFR下降,因此已停止。随后启动了羟基脲,显示降低血管闭塞危机和下蛋白尿的频率,但随后由于恶化的贫血而停止。不幸的是,她的肾小球过滤速率恶化。 AA淀粉样变性和双链DNA的抗体可能发生在镰状细胞疾病中。 ACE抑制和羟基脲减少蛋白尿,因此它们可能限制慢性肾病的进展。羟基脲还降低了血管闭塞疼痛危机的频率,因此有助于限制肾AA淀粉样症的进展。然而,需要进一步的研究来确定镰状细胞疾病中AA淀粉样变性的最佳治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号